Previous reports testing the efficacy of PI3K/mTOR blockade in combination with mitogen-activated protein kinase (MEK) inhibition in HNSCC32 and other tumour models30, 38 suggest that this may be the case. The gene discussed is MTOR; the disease is neoplasm.